Off-label drug beats standard options for relapsing-remitting MS

Rituximab performs better than other commonly used disease-modifying treatments for treatment-naïve, relapsing-remitting multiple sclerosis (MS), a Swedish study suggests.

Although not indicated for MS, rituximab is frequently prescribed to Swedish patients with relapsing-remitting MS so researchers took the opportunity to examine its effectiveness.